Search results
Q1 2024 FibroGen Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 7 hours agoI would like to remind you that remarks made on today's call include forward-looking statements about FibroGen. Such statements may include but are not limited to, our collaborations with < ...
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
Zacks via Yahoo Finance· 5 hours agoApellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus...
Hearing set to consider penalties for pharmaceutical company over Arkansas law | Arkansas Democrat...
Arkansas Democrat-Gazette· 2 days agoA battle between the Arkansas Insurance Department and pharmaceutical manufacturers is heating up...
Covishield: Parents File Lawsuit Against Serum Institute Amid AstraZeneca’s Report| Oneindia
Homenewshere.com· 5 days agoAfter AstraZeneca's acknowledgment of rare side effects, parents of a woman allegedly deceased...
ANGLE announces second assay with AstraZeneca as it deepens relationship with pharma giant
Proactive Investors· 4 days agoANGLE PLC (AIM:AGL, OTCQX:ANPCY) chief executive Andrew Newland joins Proactive's Stephen Gunnion...
E-Discovery Startup Fileread Hires Former AstraZeneca Head of Legal Services Josh Kreamer as GC |...
Law.com· 4 days agoE-discovery startup Fileread announced that it has hired Josh Kreamer, who most recently served as...
Carl Elliott, in ‘The Occasional Human Sacrifice,’ champions the whistleblowers of academic medicine...
The Boston Globe· 1 hour agoMy father, a pediatrician, was not one to gossip about his colleagues. The twins, he said, were...
Astrazeneca plc ADR (AZN) Has A Gold Mine On Its Hands – Stocks Register
Stocks Register· 6 days agoAstrazeneca plc ADR (NASDAQ:AZN) at last check was buoying at $76.06 on Thursday, May 02, with a fall of -0.46% from its closing price on previous day. Taking a look at stock ...
ANGLE teams up with AstraZeneca on a second assay
Proactive Investors· 5 days agoANGLE PLC (AIM:AGL, OTCQX:ANPCY), a leader in liquid biopsy technology, has signed a supplier agreement with AstraZeneca PLC (LSE:AZN) to develop an...
In re Cellect Poses an Obvious Dilemma | JD Supra
JD Supra· 13 hours agoIn August 2023, the Federal Circuit in In re Cellect held that in evaluating unpatentability for obviousness-type double patenting (ODP) of a patent...
